Imperial College London

ProfessorNicholasGrassly

Faculty of MedicineSchool of Public Health

Prof of Infectious Disease & Vaccine Epidemiology
 
 
 
//

Contact

 

n.grassly Website

 
 
//

Location

 

1102Building E - Sir Michael UrenWhite City Campus

//

Summary

 

Summary

Nicholas Grassly is a Professor in the Department for Infectious Disease Epidemiology, head of the Vaccine Epidemiology Research Group and associate director of the MRC Centre for Global Infectious Disease Analysis. He works on vaccine trials and disease surveillance. His research brings together epidemiological analysis and laboratory testing to identify optimal methods for disease prevention, focusing on pathogens in low- and middle-income countries such as polio, rotavirus and typhoid. He works with a network of collaborators at institutes worldwide, including in the UK, DRC, France, Ghana, India, Malawi, Pakistan and Zambia. 

He studied biology at Oxford University, trained in epidemiology at Imperial College London and learnt mathematics with the Open University. He was a Royal Society URF (2004-2011) and then Professor at Imperial College London (2011-present). He has served on various boards and committees, including the MRC Infections and Immunity Board (2012-16), the WHO SAGE polio group (2008-2020) and WHO SAGE COVID-19 vaccines working group (2020-2021). He teaches on the MSc (Epidemiology), MPH and undergraduate biomedical courses at Imperial College London. His work is funded by the MRC, Wellcome Trust, Royal Society, WHO and the Bill and Melinda Gates Foundation.

Current research topics: Rapid diagnostics for poliovirus surveillance; Epidemiology of polio eradication and endgame strategy; Environmental surveillance; Vaccine clinical trial design; Causes of oral vaccine failure (rotavirus and poliovirus); Human infection challenge for vaccine development; Typhoid epidemiology


Publications

Journals

Gray E, Cooper L, Bandyopadhyay A, et al., 2023, The origins and risk factors for serotype-2 vaccine-derived poliovirus (VDPV2) emergences in Africa during 2016-2019, Journal of Infectious Diseases, ISSN:0022-1899

Klapsa D, Wilton T, Zealand A, et al., 2022, Sustained detection of type 2 poliovirus in London sewage between February and July, 2022, by enhanced environmental surveillance, The Lancet, Vol:400, ISSN:0140-6736, Pages:1531-1538

Macklin GR, Goel AK, Mach O, et al., 2022, Epidemiology of type 2 vaccine-derived poliovirus outbreaks between 2016 and 2020, Vaccine, ISSN:0264-410X

Shaw A, Cooper L, Gumede N, et al., 2022, Time taken to detect and respond to polio outbreaks in Africa and the potential impact of direct molecular detection and nanopore sequencing, Journal of Infectious Diseases, Vol:226, ISSN:0022-1899, Pages:453-462

Williams LR, Ferguson NM, Donnelly CA, et al., 2022, Measuring vaccine efficacy against infection and disease in clinical trials: sources and magnitude of bias in COVID-19 vaccine efficacy estimates, Clinical Infectious Diseases, Vol:75, ISSN:1058-4838, Pages:e764-e773

More Publications